Overview

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib administered orally over a range of doses in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Chipscreen Biosciences, Ltd.
Treatments:
Chiauranib